~1 spots leftby Aug 2026

Proton Beam Therapy for Chondrosarcoma

Recruiting in Palo Alto (17 mi)
+1 other location
DG
Overseen byDavid R. Grosshans
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: M.D. Anderson Cancer Center
No Placebo Group
Prior Safety Data
Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

The goal of this clinical research study is to learn if proton beam therapy, with or without photon beam radiation therapy, is effective in the treatment of skull base chondrosarcoma. The safety of this treatment will also be studied.

Research Team

DG

David R. Grosshans

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for individuals with a type of bone cancer called chondrosarcoma located at the base of the skull. Participants should have had most of their tumor surgically removed, be able to perform daily activities with minimal assistance (Karnofsky Performance status ≥60), and must provide signed consent. They cannot join if they have cancer spread throughout the body or previous radiation treatment to the skull base.

Inclusion Criteria

I've had a detailed brain scan at M. D. Anderson within the last 3 months.
I've had surgery to remove as much of my skull base tumor as possible.
My cancer is a Grade 1-3 chondrosarcoma located at the base of my skull.
See 2 more

Exclusion Criteria

I have had radiation treatment on the base of my skull.
My cancer has spread to other parts of my body.

Treatment Details

Interventions

  • Proton Beam Therapy (Proton Beam Therapy)
Trial OverviewThe study is examining how effective proton beam therapy is on its own or combined with photon beam radiation in treating skull base chondrosarcoma. Researchers want to see how well these therapies work and monitor their safety for patients.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Proton Beam TherapyExperimental Treatment1 Intervention
Proton Beam Therapy - A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.

Proton Beam Therapy is already approved in Japan, Canada for the following indications:

🇯🇵
Approved in Japan as Proton Beam Therapy for:
  • Various cancers including prostate, liver, and ocular melanoma
🇨🇦
Approved in Canada as Proton Therapy for:
  • Various cancers including ocular melanoma and certain pediatric cancers

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+
Dr. Peter WT Pisters profile image

Dr. Peter WT Pisters

M.D. Anderson Cancer Center

Chief Executive Officer since 2017

MD from University of Western Ontario

Dr. Jeffrey E. Lee profile image

Dr. Jeffrey E. Lee

M.D. Anderson Cancer Center

Chief Medical Officer

MD from Stanford University School of Medicine